ES2509892T3 - Administración de un agente para limpieza del intestino y antibiótico para el tratamiento de enfermedad intestinal - Google Patents

Administración de un agente para limpieza del intestino y antibiótico para el tratamiento de enfermedad intestinal Download PDF

Info

Publication number
ES2509892T3
ES2509892T3 ES09743658.8T ES09743658T ES2509892T3 ES 2509892 T3 ES2509892 T3 ES 2509892T3 ES 09743658 T ES09743658 T ES 09743658T ES 2509892 T3 ES2509892 T3 ES 2509892T3
Authority
ES
Spain
Prior art keywords
administration
agent
antibiotic
treatment
intestinal disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES09743658.8T
Other languages
English (en)
Inventor
Lorin Johnson
William Forbes
Stephana Patton
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Salix Pharmaceuticals Ltd
Original Assignee
Salix Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Salix Pharmaceuticals Ltd filed Critical Salix Pharmaceuticals Ltd
Application granted granted Critical
Publication of ES2509892T3 publication Critical patent/ES2509892T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/42—Phosphorus; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Uso de un agente de limpieza del tracto gastrointestinal (GI) limpiador y una cantidad terapéuticamente eficaz de la rifaximina para la fabricación de un medicamento para tratar la enfermedad intestinal (EI), que comprende: administrar el agente de limpieza gastrointestinal (GI) a un sujeto en que lo necesite; y administrar la cantidad terapéuticamente eficaz de rifaximina, en el que la administración del agente de limpieza gastrointestinal (GI) está dentro de entre aproximadamente 1 a aproximadamente 90 días antes de la administración de la rifaximina.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9
imagen10
imagen11
imagen12
imagen13
imagen14
imagen15
imagen16
imagen17
imagen18
imagen19
imagen20
imagen21
imagen22
imagen23
imagen24
imagen25
imagen26
imagen27
imagen28
imagen29

Claims (1)

  1. imagen1
ES09743658.8T 2008-05-07 2009-05-07 Administración de un agente para limpieza del intestino y antibiótico para el tratamiento de enfermedad intestinal Active ES2509892T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5134108P 2008-05-07 2008-05-07
US51341P 2008-05-07
PCT/US2009/043138 WO2009137672A1 (en) 2008-05-07 2009-05-07 Methods of treating bowel disease by administering a bowel cleanser and an antibiotic

Publications (1)

Publication Number Publication Date
ES2509892T3 true ES2509892T3 (es) 2014-10-20

Family

ID=41265004

Family Applications (1)

Application Number Title Priority Date Filing Date
ES09743658.8T Active ES2509892T3 (es) 2008-05-07 2009-05-07 Administración de un agente para limpieza del intestino y antibiótico para el tratamiento de enfermedad intestinal

Country Status (12)

Country Link
US (2) US20090324736A1 (es)
EP (1) EP2294012B1 (es)
JP (1) JP5752032B2 (es)
AU (1) AU2009244190B2 (es)
CA (1) CA2723752A1 (es)
DK (1) DK2294012T3 (es)
ES (1) ES2509892T3 (es)
HR (1) HRP20140939T1 (es)
PL (1) PL2294012T3 (es)
PT (1) PT2294012E (es)
SI (1) SI2294012T1 (es)
WO (1) WO2009137672A1 (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1698630T1 (sl) 2005-03-03 2015-01-30 Alfa Wassermann S.P.A. Nove polimorfne oblike rifaksimina, postopki za njihovo pripravo in njihova uporaba v medicinskih pripravkih
ITBO20050123A1 (it) 2005-03-07 2005-06-06 Alfa Wassermann Spa Formulazioni farmaceutiche gastroresistenti contenenti rifaximina
EP2069363B1 (en) 2006-09-22 2013-03-20 Cipla Ltd. Rifaximin in an amorphous form
US8486956B2 (en) 2008-02-25 2013-07-16 Salix Pharmaceuticals, Ltd Forms of rifaximin and uses thereof
WO2009108730A2 (en) 2008-02-25 2009-09-03 Salix Pharmaceuticals, Ltd. Forms of rifaximin and uses thereof
US9603876B2 (en) 2008-09-25 2017-03-28 New York University Compositions and methods for restoring gastrointestinal microbiota following antibiotic treatment
US8916193B2 (en) 2008-12-10 2014-12-23 Cipla Limited Rifaximin complexes
RU2012126084A (ru) * 2009-11-23 2013-12-27 Сипла Лимитед Пенная композиция для местного применения
US8532349B2 (en) 2010-02-02 2013-09-10 Omnivision Technologies, Inc. Encapsulated image acquisition devices having on-board data storage, and systems, kits, and methods therefor
ES2951828T3 (es) 2010-09-23 2023-10-25 Leading Biosciences Inc Administración de inhibidores de serina proteasa al estómago
TWI535461B (zh) 2011-03-11 2016-06-01 諾金私人有限公司 結腸清潔溶液、用於製備該溶液之組成物、包含該組成物或溶液之套組、與製備該溶液之方法
US8778907B2 (en) 2011-04-27 2014-07-15 Cumberland Pharmaceuticals Lactulose for bowel evacuation
EP2874624B8 (en) * 2012-07-17 2019-10-02 Bayer New Zealand Limited Injectable antibiotic formulations and their methods of use
KR20170098980A (ko) 2012-09-11 2017-08-30 노어긴 비.브이. Peg 및 아스코르베이트를 포함하는 조성물
EP2895169A4 (en) * 2012-09-12 2016-02-24 Salix Pharmaceuticals Inc METHODS OF ADMINISTERING RIFAXIMINE WITHOUT PRODUCING ANTIBIOTIC RESISTANCE
EP2894982A4 (en) * 2012-09-13 2016-06-22 Salix Pharmaceuticals Inc METHODS OF IMPROVING LONG-TERM SURVIVAL AND REDUCING HOSPITAL RE-EMISSION RATES IN PATIENTS WITH HEPATIC ENCEPHALOPATHY
CA2903283C (en) 2013-03-15 2023-09-05 Braintree Laboratories, Inc. Dual use oral pharmaceutical composition tablets of sulfate salts and methods of use thereof
CN105307654B (zh) * 2013-04-30 2022-06-07 托马斯·朱利叶斯·波洛迪 用于治疗微生物区系相关的精神病况和疾病的组合物和方法
CA2912712A1 (en) * 2013-05-17 2014-11-20 Salix Pharmaceuticals, Inc. Methods of using rifaximin in position emission tomography (pet) scans
WO2014201037A2 (en) * 2013-06-10 2014-12-18 New York University Methods for manipulating immune responses by altering microbiota
KR101423005B1 (ko) 2013-10-17 2014-07-28 강윤식 장 세정용 조성물
US9387199B2 (en) * 2013-11-12 2016-07-12 University Of Virginia Patent Foundation Compositions and methods for treating clostridium infection and preventing recurrence of infection
EP3122349B1 (en) 2014-03-25 2021-12-22 Leading Biosciences, Inc. Compositions for the treatment of autodigestion
EA201692106A1 (ru) 2014-04-29 2017-04-28 КОЛОНАРИКОНСЕПТС ЭлЭлСи Пищевые продукты, системы, способы и наборы для замены электролитов
CN106999477B (zh) * 2014-06-30 2020-04-10 萨利克斯药品公司 用于重复治疗肠易激综合征(ibs)的方法
HK1247283A1 (zh) 2015-03-02 2018-09-21 科罗纳里康赛普茨有限责任公司 用於peg代谢物及peg分解产物检测的化合物及方法
HRP20200432T1 (hr) 2015-04-02 2020-06-12 Theravance Biopharma R&D Ip, Llc Oblik za kombinacijsko doziranje antagonista mu opioidnog receptora i opioidnog sredstva
KR102619907B1 (ko) * 2015-08-17 2024-01-02 서화수 가축설사 치료용 복합제 조성물
CA3010865A1 (en) * 2016-01-08 2017-07-13 Colonaryconcepts Llc Food based delivery of therapeutic agent for treatment of hepatic encephalopathy
US10653728B2 (en) 2016-10-17 2020-05-19 New York University Probiotic compositions for improving metabolism and immunity
PL3416627T3 (pl) * 2017-04-26 2020-06-01 Sandoz Ag Doustna postać dawkowania zawierająca rifaksyminę w postaci beta
EP3737380A4 (en) * 2018-01-11 2021-09-29 Meritage Pharma, Inc. STABLE CORTICOSTEROID COMPOSITIONS
WO2019178652A1 (en) * 2018-03-23 2019-09-26 Borody Thomas J Compositions and methods for treating inflammatory bowel disease and fusobacteria-caused or related diseases and conditions

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3363997A (en) 1958-12-22 1968-01-16 Monsanto Co Composition of matter and process
IT1154655B (it) 1980-05-22 1987-01-21 Alfa Farmaceutici Spa Derivati imidazo-rifamicinici metodi per la loro preparazione e loro uso come sostanza ad azione antibatterica
IT1199374B (it) 1984-05-15 1988-12-30 Alfa Farmaceutici Spa Processo per la preparazione di pirido-imidazo-rifamicine
US4883785A (en) * 1984-07-27 1989-11-28 Chow Wing Sun Complex of anti-fungal agent and cyclodextrin and method
AU6196786A (en) 1985-08-01 1987-03-05 Braintree Laboratories Inc. Low-sodium laxative and lavage formulation
DE3889547T2 (de) 1987-12-24 1994-11-17 Borody Thomas J Orthostatische waschlösungen.
US6861053B1 (en) * 1999-08-11 2005-03-01 Cedars-Sinai Medical Center Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
DK1017404T3 (da) * 1997-09-26 2004-11-01 Celltech Pharma Europ Ltd Farmaceutisk sammensætning til behandling af inflammatorisk tarmsygdom
AUPQ899700A0 (en) * 2000-07-25 2000-08-17 Borody, Thomas Julius Probiotic recolonisation therapy
JP2005526059A (ja) * 2002-03-07 2005-09-02 アドバンシス ファーマスーティカル コーポレイション 抗生物質組成物
AU2003260736B8 (en) * 2002-08-26 2009-04-23 S.L.A. Pharma Ag A pharmaceutical composition
GB0224909D0 (en) * 2002-10-25 2002-12-04 Norgine Europe Bv Colon cleansing compositions
ITMI20032144A1 (it) 2003-11-07 2005-05-08 Alfa Wassermann Spa Forme polimorfe di rifaximina, processi per ottenerle e
US7687075B2 (en) * 2003-11-19 2010-03-30 Salix Pharmaceuticals, Ltd. Colonic purgative composition with soluble binding agent
SI1698630T1 (sl) 2005-03-03 2015-01-30 Alfa Wassermann S.P.A. Nove polimorfne oblike rifaksimina, postopki za njihovo pripravo in njihova uporaba v medicinskih pripravkih
WO2006102536A2 (en) 2005-03-23 2006-09-28 University Of Southern California Treatment of disease conditions through modulation of hydrogen sulfide produced by small intestinal bacterial overgrowth
AU2006244112B2 (en) * 2005-05-06 2011-02-17 Salix Pharmaceuticals, Inc. Polyethylene glycol colonic purgative composition
ES2747259T3 (es) * 2006-03-09 2020-03-10 Salix Pharmaceuticals Inc Preparación anti-disfunción rectal de rifaximina
US20100069421A1 (en) * 2006-08-02 2010-03-18 Doug Bettenhausen Compositions and methods for the treatment of radiation proctosigmoitis
US20080085524A1 (en) 2006-08-15 2008-04-10 Prometheus Laboratories Inc. Methods for diagnosing irritable bowel syndrome
EP2201372A4 (en) * 2007-10-17 2010-11-10 Salix Pharmaceuticals Ltd NEW THERAPEUTIC TARGET MOLECULES IN STOMACH DISEASES
WO2019023892A1 (en) 2017-07-31 2019-02-07 SZ DJI Technology Co., Ltd. MOTION-BASED IMPRESSION CORRECTION IN POINT CLOUDS
US11960008B2 (en) 2018-05-17 2024-04-16 Cmos Sensor, Inc. Method and system for pseudo 3D mapping in robotic applications
KR102382079B1 (ko) 2020-02-11 2022-03-31 효성중공업 주식회사 에어갭 조절장치
US11963008B2 (en) 2020-11-25 2024-04-16 Truist Bank Geolocation-based notifications using relationships in separate systems

Also Published As

Publication number Publication date
US20090324736A1 (en) 2009-12-31
EP2294012A4 (en) 2011-10-26
HK1156293A1 (en) 2012-06-08
PT2294012E (pt) 2014-10-15
HRP20140939T1 (hr) 2014-11-21
PL2294012T3 (pl) 2014-12-31
EP2294012B1 (en) 2014-07-09
JP5752032B2 (ja) 2015-07-22
WO2009137672A1 (en) 2009-11-12
JP2011519952A (ja) 2011-07-14
AU2009244190A1 (en) 2009-11-12
SI2294012T1 (sl) 2014-11-28
DK2294012T3 (da) 2014-10-06
AU2009244190B2 (en) 2016-02-25
EP2294012A1 (en) 2011-03-16
US20130164384A1 (en) 2013-06-27
CA2723752A1 (en) 2009-11-12

Similar Documents

Publication Publication Date Title
CL2021000622A1 (es) Uso de niclosamida para la preparación de un medicamento para el tratamiento de colitis autoinmune, una enfermedad inflamatoria intestinal, colitis autoinmune iatrogénica, divisional de la solicitud de patente nº 559-2018.
ES2526648T3 (es) Método para mejorar el estrés oxidativo y la memoria de trabajo mediante la administración de pterostilbeno
CU20070203A7 (es) Composición farmacéutica que comprende una difenilurea sustituida con omega-carboxiarilo para el tratamiento del cáncer
ECSP099436A (es) Acilaminopirazoles como inhibidores de fgfr
EP2248519A3 (en) Non-mucoadhesive film dosage forms
CL2012000794A1 (es) Composicion farmaceutica solida de desintegracion oral que comprende 20 mg o menos de un un corticoesteroide y un desintegrador; tableta que se desintegra oralmente; y su uso en el tratamiento de una afeccion inflamatoria del tracto gastrointestinal como inflamacion del esofago, glosis, epiglotis, amigdalas, orofaringea, entre otras.
EA200900155A1 (ru) Модуляторы фармакокинетических свойств лекарственных средств
EA201300121A1 (ru) Ингибитор дпп-4 в комбинации с дополнительным противодиабетическим агентом, таблетки, включающие указанные композиции, их применение и способ их получения
AR070047A1 (es) Tratamientos terapeuticos contra el cancer. composicion que comprende un inhibidor de hedgehog.
UY30158A1 (es) Uso de derivados de benzo-heteroaril sulfamida para el tratamiento del dolor
CL2011000099A1 (es) Uso de una beta-defensina humana en la manufactura de un medicamento que sirve para el tratamiento de una enfermedad intestinal inflamatoria.
AR090885A1 (es) Uso de laquinimod en alta dosis para el tratamiento de la esclerosis multiple
AR077125A1 (es) Combinaciones farmaceuticas utiles para tratar el vhc
EP4309722A3 (en) Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
AR059357A1 (es) Formulaciones farmaceuticas
EA200801698A1 (ru) Лекарственные композиции для применения в вагине
FI20095600A7 (fi) Koostumus ihosairauksien hoitoa varten
AR117614A1 (es) Forma de dosificación farmacéutica administrable por vía oral con liberación modificada
ECSP077843A (es) Tratamiento o prevención del prurito
AR065582A1 (es) Mejoras en composiciones medicinales o relativas a las mismas
ES2525931T3 (es) Composiciones y métodos para prevenir o tratar enfermedad inflamatoria intestinal
AR048806A1 (es) Uso de cariofilenos en la elaboracion de medicamentos y tratamiento de afecciones corporales de inflamacion y dolor inflamatorio
AR045070A1 (es) Preparados farmaceuticos topicos de acido ascorbico con efecto post-antimicotico
CL2009000878A1 (es) Compuestos derivados de sulfonamida; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como dolor, migraña, diabetes, enfermedades del tracto respiratorio, enfermedades intestinales inflamatorias, obesidad, entre otras.
AR057876A1 (es) Tratamiento de pacientes con enfermedad renal cronica (erc) utilizando compuestos de la invencion